Compounded drugs as an alternative to the therapeutical gaps of inborn errors of metabolism
DOI:
https://doi.org/10.1590/s2175-97902023e21109Keywords:
Rare diseases, Metabolism, Inborn errors, Therapeutic gap, Compounded drugsAbstract
Inborn errors of metabolism are rare disorders with few therapeutic options for their treatments, which can make patients suffer with complications. Therefore, compounded drugs might be a promising option given that they have the ability of meeting the patient’s specific needs, (i) identification of the main drugs described in the literature; (ii) proposal of compounding systems and (iii) calculation of the budgetary addition for the inclusion of these drugs into the Brazilian Unified Health System. The research conducted a literature review and used management data as well as data obtained from official Federal District government websites. The study identified 31 drugs for the treatment of inborn errors of metabolism. Fifty eight percent (58%) (18) of the medicines had their current demand identified, which are currently unmet by the local Health System. The estimated budget for the production of compounded drugs was of R$363,16.98 per year for approximately 300 patients. This estimated cost represents a budgetary addition of only 0.17% from the total of expenditures planned for drug acquirement. There is a therapeutic gap for inborn errors of metabolism and compounding pharmacies show potential in ensuring access to medicine therapy with a low-cost investment.
Downloads
References
Alfadhel M, Al-Thihli K, Moubayed H, Eyaid W, Al-Jeraisy M. Drug treatment of inborn errors of metabolism: a systematic review. Arch Dis Child. 2013;98(6):454-461.
Baumgartner, M.R. et al. Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia. Orphanet Journal of Rare Diseases. 2014; 9(1), pp. 1-36. doi: 10.1186/s13023-014-0130-8.
» https://doi.org/10.1186/s13023-014-0130-8.
Borella JC, Pereira LHTR. Produção e avaliação comparativa de preços de produtos do Laboratório de Manipulação Farmacêutica - Ribeirão Preto - SP: experiência relacionada à Assistência Farmacêutica no SUS. Cad. Saude Coletiva. 2017;25(2):210-216.
BRASIL. Portaria no 29, de 15 de Agosto de 2018. Ministério da Saúde/Secretaria Ciência, Tecnol. e Insumos Estratégicos. Edição: 15. 2018;65.
Camp KM, Lloyd-Puryear MA, Huntington KL. Nutritional treatment for inborn errors of metabolism: indications, regulations, and availability of medical foods and dietary supplements using phenylketonuria as an example. Mol Genet Metab. 2012;107(1-2):3-9.
Comissão Nacional de Incorporação de Tecnologias no SUS - CONITEC. Biotina para o Tratamento da Deficiência de Biotinidase. Relatório de Recomendação 06. 2012; pp 1-17.
Comissão Nacional de Incorporação de Tecnologias no SUS - CONITEC. Sapropterina para o tratamento da fenilcetonúria. Relatório Recom. 2018a;1-90.
Comissão Nacional de Incorporação de Tecnologias no SUS - CONITEC. Alfaelosulfase para o tratamento da mucopolissacaridose tipo IVa (Síndrome de Morquio A). Relatório Recom. 2018b;1-35.
Comissão Nacional de Incorporação de Tecnologias no SUS - CONITEC. Galsulfase para o tratamento da mucopolissacaridose tipo VI. Relatório Recom. 2018c;1-38.
Comissão Nacional de Incorporação de Tecnologias no SUS - CONITEC. Laronidase como terapia de reposição enzimática na mucopolissacaridose tipo I. Relatório Recom. 2017a;1-38.
Comissão Nacional de Incorporação de Tecnologias no SUS - CONITEC. Idursulfase como terapia de reposição enzimática na mucopolissacaridose tipo II. Relatório Recom. 2017b;1-43.
Costa PQ, Lima JES, Coelho HLL. Prescrição e preparo de medicamentos sem formulação adequada para crianças: um estudo de base hospitalar. Braz J Pharm Sci. 2009;45(1):57-66.
Cunningham, A. et al. Recommendations for the use of sapropterin in phenylketonuria. Molecular Genetics and Metabolism. 2012; 106(3) pp. 269-276. Available at: http://dx.doi.org/10.1016/j.ymgme.2012.04.004
» http://dx.doi.org/10.1016/j.ymgme.2012.04.004
Davidson, M.H. A systematic review of bile acid sequestrant therapy in children with familial hypercholesterolemia. Journal of Clinical Lipidology. 2011; 5(2) pp. 76-81. Available at: http://dx.doi.org/10.1016/j.jacl.2011.01.005
» http://dx.doi.org/10.1016/j.jacl.2011.01.005
Demirdas S, Kessel IN van, Kordewal MJ, Hollak CEM, Meutgeert H, Klaren A, et al. Clinical pathways for inborn errors of metabolism: warranted and feasible. Orphanet J Rare Dis. 2013;8:37.
Diekman, E.F., De Koning, T.J., Verhoeven-Duif, N.M., Rovers, M.M. and Van Hasselt, P.M. Survival and psychomotor development with early betaine treatment in patients with severe methylenetetrahydrofolate reductase deficiency. JAMA Neurology. 2014; 71(2), pp. 188-194. doi: 10.1001/jamaneurol.2013.4915.
» https://doi.org/10.1001/jamaneurol.2013.4915.
El-Hattab AW. Inborn errors of metabolism. Clin Perinatol. 2015;42(2):413-439.
El Husny AS, Caldato MCF. Erros Inatos do Metabolismo: Revisão de Literatura. Rev Para Med. 2006;20(2):41-45.
Fachini AS. Medicamentos magistrais como alternativa terapêutica para erros inatos do metabolismo. 2019. - Universidade de Brasilia, Brasilia-DF, 2019.
Frazier, D.M. et al. Nutrition management guideline for maple syrup urine disease: An evidence- and consensus-based approach. Molecular Genetics and Metabolism . 2014; 112(3) pp. 210-217. Available at: http://dx.doi.org/10.1016/j.ymgme.2014.05.006
» http://dx.doi.org/10.1016/j.ymgme.2014.05.006
Häberle, J. et al. Suggested guidelines for the diagnosis and management of urea cycle disorders. Orphanet Journal of Rare Diseases . 2012; 42(6), pp. 1192-1230. doi: 10.1002/ jimd.12100.
» https://doi.org/10.1002/ jimd.12100.
Gambello MJ, Li H. Current strategies for the treatment of inborn errors of metabolism. J Genet Genomics. 2018;45(2):61-70.
Jardim LB, Ashton-Prolla P. Erros inatos do metabolismo em crianças e recém-nascidos agudamente enfermos: guia para o seu diagnóstico e manejo. J Pediatr (Rio J). 1996;72(2):63-70.
Kölker, S. et al. Diagnosis and management of glutaric aciduria type I - revised recommendations. Journal of Inherited Metabolic Disease. 2011; 34(3), pp. 677-694. doi: 10.1007/s10545-011-9289-5.
» https://doi.org/10.1007/s10545-011-9289-5.
Lilliu, F. Treatment of organic acidurias and urea cycle disorders. Journal of Maternal-Fetal and Neonatal Medicine. 2010; 23 (SUPPL. 3), pp. 73-75. doi: 10.3109/14767058.2010.509932.
» https://doi.org/10.3109/14767058.2010.509932.
MacLeod, E.L. and Ney, D.M. Nutritional management of phenylketonuria. Annales Nestle. 2010; 68(2), pp. 58-69. doi: 10.1159/000312813.
» https://doi.org/10.1159/000312813.
Morris, A.A.M. et al. Guidelines for the diagnosis and management of cystathionine beta-synthase deficiency. Journal of Inherited Metabolic Disease . 2017; 40(1), pp. 49-74. doi: 10.1007/s10545-016-9979-0.
» https://doi.org/10.1007/s10545-016-9979-0.
Murray CJL, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2197-223.
O’Gorman, C.S., Higgins, M.F. and O’Neill, M.B. Systematic review and metaanalysis of statins for heterozygous familial hypercholesterolemia in children: Evaluation of cholesterol changes and side effects. Pediatric Cardiology. 2009; 30(4), pp. 482-489. doi: 10.1007/s00246-008-9364-3.
» https://doi.org/10.1007/s00246-008-9364-3.
Pailaquilén RMB, Medina EU. A revisão sistemática e a sua relação com a prática baseada na evidência em saúde. Rev Latino-Am Enferm. 2010;18(4):1-8.
Pereira ACS, Miranda ES, Castilho SR, Futuro DO, Teixeira LA, Paula GR. Medicamentos magistrais em recém-nascidos e crianças hospitalizados. Rev Paul Pediatr. 2016;34(4):403-407.
Rowe RC, Shesekey PJ, Quinn M. Handbook of Pharmaceutical Excipients. 2009;917.
Schiff, M. and Blom, H.J. Treatment of inherited homocystinurias. Neuropediatrics. 2012; 43(6), pp. 295-304. doi: 10.1055/s-0032-1329883.
» https://doi.org/10.1055/s-0032-1329883.
Schwartz IV, Souza CFM, Giugliani R. Treatment of inborn errors of metabolism. J Pediatr. (Rio J). 2008;84(4 Sup):S8-S19.
Singh, R.H. et al. Updated, web-based nutrition management guideline for PKU: An evidence and consensus based approach. Molecular Genetics and Metabolism . 2016; 118(2), pp. 72-83. doi: 10.1016/j.ymgme.2016.04.008.
» https://doi.org/10.1016/j.ymgme.2016.04.008.
Somaraju, U.R. and Merrin, M. Sapropterin dihydrochloride for phenylketonuria. Cochrane Database of Systematic Reviews 2015(3). 2015 doi: 10.1002/14651858.CD008005.pub4.
» https://doi.org/10.1002/14651858.CD008005.pub4.
Sutton, V.R. et al. Chronic management and health supervision of individuals with propionic acidemia. Molecular Genetics and Metabolism . 2012; 105(1), pp. 26-33. Available at: http://dx.doi.org/10.1016/j.ymgme.2011.08.034
» http://dx.doi.org/10.1016/j.ymgme.2011.08.034
Sweetman SC, Blake PS, Brayfield A, McGlashan JM, Neathercoat GC, Parsons AV. Martindale: The Complete Drug References. Pharmaceutical Press, Gurnee. 2009.
Van Vliet, D., Derks, T.G., Van Rijn, M., De Groot, M.J., Macdonald, A., Heiner-Fokkema, M.R. and Van Spronsen, F.J. Single amino acid supplementation in aminoacidopathies: A systematic review. Orphanet Journal of Rare Diseases . 2014; 9(1), pp. 1-14. doi: 10.1186/1750-1172-9-7.
» https://doi.org/10.1186/1750-1172-9-7.
Vuorio, A. et al. Statins for children with familial hypercholesterolemia. Cochrane Database of Systematic Reviews 2019(11). 2017. doi: 10.1002/14651858.CD006401. pub5.
» https://doi.org/10.1002/14651858.CD006401. pub5.
Wagner CA. Metabolic acidosis: new insights from mouse models. Curr Opin Nephrol Hypertens. 2007;16(5):471-476.
Waters D, Adeloye D, Woolham, Wastnedge E, Patel S, Rudan I. Global birth prevalence and mortality from inborn errors of metabolism: a systematic analysis of the evidence. J Glob Health. 2018;8(2):1-12.
Wilcken B. Rare diseases and the assessment of intervention: What sorts of clinical trials can we use? J Inherit Metab Dis. 2001;24(2):291-298.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.
